Lineage Cell Therapeutics (NYSEAMERICAN:LCTX - Get Free Report) is expected to post its Q1 2025 quarterly earnings results after the market closes on Tuesday, May 13th. Analysts expect Lineage Cell Therapeutics to post earnings of ($0.02) per share and revenue of $1.72 million for the quarter.
Lineage Cell Therapeutics Stock Down 5.1 %
LCTX stock traded down $0.02 during trading on Tuesday, reaching $0.44. The stock had a trading volume of 743,472 shares, compared to its average volume of 1,310,041. The company has a market capitalization of $95.88 million, a price-to-earnings ratio of -3.63 and a beta of 1.21. Lineage Cell Therapeutics has a one year low of $0.37 and a one year high of $1.35. The company's 50 day moving average is $0.48 and its two-hundred day moving average is $0.64.
Analyst Ratings Changes
Several equities analysts have recently weighed in on the stock. D. Boral Capital reiterated a "buy" rating and issued a $2.00 target price on shares of Lineage Cell Therapeutics in a research note on Tuesday, March 11th. HC Wainwright restated a "buy" rating and set a $9.00 price objective on shares of Lineage Cell Therapeutics in a research report on Tuesday, March 11th. Maxim Group reduced their price target on shares of Lineage Cell Therapeutics from $5.00 to $3.00 and set a "buy" rating on the stock in a research report on Friday, January 10th. Finally, B. Riley lowered their target price on Lineage Cell Therapeutics from $4.00 to $3.00 and set a "buy" rating for the company in a research note on Friday, March 14th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $4.20.
Get Our Latest Research Report on Lineage Cell Therapeutics
Lineage Cell Therapeutics Company Profile
(
Get Free Report)
Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.
Further Reading
Before you consider Lineage Cell Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lineage Cell Therapeutics wasn't on the list.
While Lineage Cell Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
